|
|
|
LAGUNA HILLS, CA--(Marketwire - November 19, 2009) - Allied Schools, a provider of online education, is proud to announce that alumnus Margaret Jones of Aliso Viejo, CA was awarded the 2010 Distance Education and Training...
ALISO VIEJO, CA--(Marketwire - November 18, 2009) - In a continuing effort to keep shareholders and the public informed, WiFi Wireless, Inc. ( PINKSHEETS : WFWL ) wishes to disclose the following information*. 1) WiFi announced...
ALISO VIEJO, Calif.----Quest Software, Inc. has updated Quest® ActiveRoles™ Server, its management, provisioning and security platform, which includes elevated requests and approval workflow to better manage accountability...
ALISO VIEJO, Calif., Nov. 17 /PRNewswire/ -- OCTANe hosted nearly 700 leading medical device industry executives from over 425 companies to discuss promising technology and emerging trends for the medical device industry last...
ALISO VIEJO, Calif.----AVANIR Pharmaceuticals, Inc. today announced that it will release unaudited financial results for the quarter and fiscal year ended September 30, 2009 before market open on Tuesday, November 24, 2009.
ALISO VIEJO, Calif., Nov. 17, 2009 (GLOBE NEWSWIRE) -- QLogic Corp. (Nasdaq:QLGC), a leading supplier of high performance network infrastructure solutions, today announced that QLogic senior executives will present at the...
ALISO VIEJO, Calif., Nov. 16, 2009 (GLOBE NEWSWIRE) -- QLogic Corp. (Nasdaq:QLGC), a leading supplier of high performance network infrastructure solutions, today announced the industry's first combination 8Gb Fibre Channel/1Gb...
ALISO VIEJO, Calif., Nov. 11, 2009 (GLOBE NEWSWIRE) -- QLogic Corp. (Nasdaq:QLGC) today announced that it continues to strengthen its number one position in storage area network (SAN) Fibre Channel adapters as it increased its...
ALISO VIEJO, Calif.----AVANIR Pharmaceuticals, Inc. today announced that the Company will present at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18th at 3:15 p.m.
ALISO VIEJO, Calif.----AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational...
